Sept 27 (Reuters) – Amgen Inc said on Tuesday its
cancer drug Kyprolis failed to meet the main goal of a
late-stage study against Takeda Pharmaceutical Co Ltd’s
Velcade for treating newly diagnosed…
The post Amgen’s multiple myeloma drug falls short in late stage study appeared first on NASDAQ.